Navigation Links
Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
Date:8/21/2012

PHILADELPHIA, Aug. 21, 2012 /PRNewswire/ -- Abbott Laboratories, a pharmaceutical company that has already pleaded guilty and agreed to pay $1.5 billion to U.S. federal and state authorities after investigations into its illegal marketing and false claims regarding its marketing of prescription drugs, now faces a lawsuit for similar practices with an entirely different drug: TriCor.  TriCor is a fibrate that was approved by the FDA for use in certain circumstances with patients with elevated triglycerides or a particular type of cholesterol imbalance.  A former employee filed a whistleblower lawsuit alleging Abbott marketed the drug to doctors in a deceptive manner – including through kickbacks, misleading and off-label marketing, resulting in hundreds of millions of dollars in inappropriate prescription costs paid by Medicare and Medicaid.  The lawsuit would seek to benefit the United States government to repay Medicare and Medicaid the prescription costs paid because of the deceptive marketing. Federal law also provides protection and compensation to employee whistleblowers who bring evidence like this to light. The lawsuit was filed by attorneys at Nicholson & Eastin, LLP and the Kelley/Uustal law firm.

The case is pending before the Honorable C. Darnell Jones, II, in the United States District Court for the Eastern District of Pennsylvania under Case No. 09-4264

For more information, or a copy of the complaint, contact Robert Nicholson, at Nicholson & Easton, LLP, Robert@nicholsonlawgroup.com or (954) 634-4400.

About Nicholson & Eastin, LLP

Robert N. Nicholson, founder of the Nicholson & Eastin firm, is a former federal prosecutor and a nationally recognized health care attorney who has extensive experience with health care fraud investigations and p
'/>"/>

SOURCE Kelley / Uustal
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. Abbott, The Abbott Fund And Direct Relief International Reach Key HIV Testing Milestones: 20 Million Tests Provided Over 10 Years, And More Than 150,000 HIV Cases Prevented In Children
3. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
4. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
5. Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
6. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
7. PDI, Inc. Announces Client FDA Product Approval Related to Previously Disclosed Contract
8. UBM Canon, the Global MedTech Authority, Partners with the World Medical Device Organization, WMDO, to Provide Medical Device Companies with Industry-Related Online Training Solutions
9. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
10. Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
11. CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... CHARLOTTESVILLE, Va. and AUSTIN, ... PhosImmune Inc. and PureMHC LLC today announced they ... to develop novel antibody-based immunotherapies designed to target ... identification of phosphorylated peptides displayed on the surfaces ... These phosphopeptide tumor targets (PTTs), derived from proteins ...
(Date:10/22/2014)... 22, 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... the  IAP310 study have been published in ... peer-reviewed journal with broad, multidisciplinary readership. IAP310 was ... safety and efficacy of Zalviso, also referred to ... the treatment of post-operative pain in patients following ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... 2011 /PRNewswire/ -- PRA, a leading Clinical ... Romania to further strengthen our coverage of the Balkan ... projects in the neighboring Republic of Moldova. ... in Romania, the PRA staff has steadily increased and ...
... Aug. 22, 2011 Reportlinker.com announces ... is available in its catalogue: ... Assessments of Leading Suppliers ... This report provides diagnostic imaging industry ...
Cached Medicine Technology:PRA Opens Office in Romania 2Global MRI Market: Strategic Assessments of Leading Suppliers 2Global MRI Market: Strategic Assessments of Leading Suppliers 3Global MRI Market: Strategic Assessments of Leading Suppliers 4Global MRI Market: Strategic Assessments of Leading Suppliers 5
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ovarian ... to think outside the bra. She doesn’t try to hide ... awareness about women’s other lady parts. , "We have won ... color pink and everybody knows what you’re talking about,” Jess-Huff ... has not been won when it comes to gynecologic cancers. ...
(Date:10/20/2014)... 2014 My Clients Plus ( http://www.MyClientsPlus.com ... The new module enables easy administration and routing ... quality care. , This application allows users such as ... attach a to-do item to a specific client, categorize ... up reoccurring reminders for follow-ups. It's designed to ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2
... technology to process the conversion of medical records from microfiche to ... ... 2009 -- Penny Imaging Exchange, Inc. (PIE) has acquired new technology ... form - the DRS Digitizer . With the Obama administration ...
... CHICAGO, April 17 Specialty Underwriters, Alliance, Inc. ... announced today that Glass Lewis & Co., a leading ... WHITE proxy card and do not vote for the nominees ... SUA,s Annual Meeting of Stockholders will be held at 9:00 ...
... Volunteer Week, is April 19 - April 25 ... today praised Pennsylvania,s volunteers for selflessly giving their time ... and urged other citizens to join those important efforts. ... opportunity to thank our volunteers for generously sharing their ...
... Assurance solutions help MEDNAX increase security and simplify ... Corporation , leaders in access governance, provisioning ... implemented the company,s Enterprise Suite to assure access ... 5,000 clinical and administrative employees. MEDNAX is ...
... such study involves effort to improve chemotherapy effectiveness , , FRIDAY, ... research and testing, only a small percentage of cancer agents ... have come up with a way to weed out the ... the marketplace. , The new model, a so-called "phase ...
... South Florida physician Sanford Siegal, D.O., M.D., explains why ... and reveals how to overcome this obstacle to reaching ... Sanford Siegal, Medical Director of Miami, Florida-based weight-loss practice, ... among dieters that the most challenging part of reaching ...
Cached Medicine News:Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 3Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 2Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 3Health News:PA Secretary of Health Recognizes Pennsylvania Volunteers; Urges Greater Citizen Involvement 2Health News:MEDNAX National Medical Group(TM) Uses Courion's Enterprise Suite to Automate Identity and Access Management 2Health News:MEDNAX National Medical Group(TM) Uses Courion's Enterprise Suite to Automate Identity and Access Management 3Health News:'Phase 0' Trials Aim to Speed Cancer Drug Development 2Health News:'Phase 0' Trials Aim to Speed Cancer Drug Development 3Health News:Losing the Last Ten Pounds is the Hardest Part of any Diet Confirms Weight-Loss Expert and Author Dr. Sanford Siegal 2
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... operations, the Sysmex KX-21N is ideal ... lab testing. This 3-part differential ... Built on the reliable, field proven ... a completely automatic START-UP function and ...
... of pacemakers features several of the ... in today's worldwide pacing market. Offering ... and diagnostic information, the system builds ... pacemakers platform. , ,It incorporates ...
... of pacemakers features several of the ... in today's worldwide pacing market. Offering ... and diagnostic information, the system builds ... pacemakers platform. , ,It incorporates ...
Medicine Products: